IDEXX Laboratories, Inc. $IDXX Shares Acquired by Beacon Investment Advisory Services Inc.

Beacon Investment Advisory Services Inc. increased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 15.7% in the third quarter, Holdings Channel.com reports. The firm owned 56,241 shares of the company’s stock after purchasing an additional 7,616 shares during the period. IDEXX Laboratories accounts for 1.5% of Beacon Investment Advisory Services Inc.’s investment portfolio, making the stock its 16th largest holding. Beacon Investment Advisory Services Inc.’s holdings in IDEXX Laboratories were worth $35,932,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in IDXX. STF Management LP boosted its stake in IDEXX Laboratories by 1.3% in the 2nd quarter. STF Management LP now owns 1,240 shares of the company’s stock worth $665,000 after buying an additional 16 shares during the last quarter. Clearstead Trust LLC lifted its holdings in shares of IDEXX Laboratories by 1.1% during the 2nd quarter. Clearstead Trust LLC now owns 1,515 shares of the company’s stock worth $813,000 after acquiring an additional 16 shares during the period. Stratos Wealth Partners LTD. boosted its position in shares of IDEXX Laboratories by 1.7% in the second quarter. Stratos Wealth Partners LTD. now owns 1,051 shares of the company’s stock worth $564,000 after acquiring an additional 18 shares during the last quarter. Private Trust Co. NA boosted its position in shares of IDEXX Laboratories by 9.4% in the third quarter. Private Trust Co. NA now owns 209 shares of the company’s stock worth $134,000 after acquiring an additional 18 shares during the last quarter. Finally, Red Spruce Capital LLC grew its holdings in IDEXX Laboratories by 1.1% in the second quarter. Red Spruce Capital LLC now owns 1,701 shares of the company’s stock valued at $912,000 after purchasing an additional 19 shares during the period. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Nimrata Hunt sold 9,425 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the sale, the executive vice president owned 21,149 shares in the company, valued at $14,874,937.66. This trade represents a 30.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.98% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Weiss Ratings downgraded shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday. UBS Group upped their price objective on IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a report on Tuesday, November 4th. Wall Street Zen lowered IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 29th. Jefferies Financial Group reiterated a “buy” rating and issued a $830.00 target price on shares of IDEXX Laboratories in a report on Tuesday, November 4th. Finally, JPMorgan Chase & Co. upped their price target on IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Seven research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and an average target price of $763.50.

IDEXX Laboratories Trading Up 0.0%

NASDAQ:IDXX opened at $688.48 on Friday. The business’s 50-day moving average is $695.70 and its two-hundred day moving average is $631.35. The firm has a market capitalization of $54.98 billion, a PE ratio of 54.60, a price-to-earnings-growth ratio of 4.11 and a beta of 1.67. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $769.98. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.18 and a quick ratio of 0.87.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.14 by $0.08. The business had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.The company’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same quarter last year, the firm earned $2.80 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Research analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.